(CercleFinance.com) – Pharnext announced on Monday the freezing of data from its pivotal phase III study in Charcot Marie-Tooth disease type 1A, the last step before the publication of the results of the clinical trial.
The verification of the integrity of clinical data and the official freezing of the database, as of December 1, will now allow the biotechnology company to unblind the treatment received by patients (PXT3003 or placebo) and to initiate the results analysis phase.
Pharnext is therefore maintaining the previously announced schedule, still aiming for the dissemination of the first data from the phase III study on December 11, as previously communicated.